The effects of FK506 on the development and expression of morphine tolerance and dependence in mice.
FK506 is an immunophilin-binding ligand that inhibits calcineurin and decreases nitric oxide (NO) production in the nervous tissues. We examined the effects in mice of systemic treatment with FK506 on the induction and expression of morphine (s.c.) tolerance and dependence and compared them with the effects of the non-specific NO synthase inhibitor, NG-nitro-L-arginine methyl ester (L-NAME), and specific inducible NO synthase inhibitor, aminoguanidine. FK506 (0.5-10 mg/kg, s.c.) exerted inhibitory effects on both development and expression of tolerance to morphine-induced antinociception. FK506 also significantly decreased the expression of morphine dependence, as assessed by naloxone-precipitated (2 mg/kg, i.p.) withdrawal syndrome, but a similar effect was not found for the development of morphine dependence. A similar pattern of effects was observed with L-NAME (3-20 mg/kg, i.p.), while aminoguanidine (50-100 mg/kg, i.p.) did not alter tolerance or dependence. Examining the possible interaction between their inhibitory effects on tolerance and dependence, we combined the subeffective doses of FK506 (0.5 or 1 mg/kg) with L-NAME (3 mg/kg) or aminoguanidine (100 mg/kg). The combination of FK506 with L-NAME, but not with aminoguanidine, significantly decreased the development and expression of tolerance and expression of dependence. These data show the effectiveness of FK506 on morphine tolerance and dependence and suggest an additive effect between FK506 and the inhibition of constitutive NO synthesis in this regard.
Homayoun
H
H
Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Khavandgar
S
S
Mehr
S Ejtemaei
SE
Namiranian
K
K
Dehpour
A R
AR
D000700:Analgesics / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D000818:Animals; D004305:Dose-Response Relationship, Drug; D004361:Drug Tolerance; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D006146:Guanidines / Q000008:administration & dosage / Q000494:pharmacology; D020104:Immunophilins / Q000378:metabolism*; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D008024:Ligands; D008297:Male; D051379:Mice; D009020:Morphine / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D009021:Morphine Dependence / Q000378:metabolism / Q000523:psychology*; D019331:NG-Nitroarginine Methyl Ester / Q000008:administration & dosage / Q000494:pharmacology; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D010147:Pain Measurement; D013375:Substance Withdrawal Syndrome / Q000209:etiology; D016559:Tacrolimus / Q000008:administration & dosage / Q000494:pharmacology*
D000700:Analgesics; D004791:Enzyme Inhibitors; D006146:Guanidines; D008024:Ligands; D009292:Narcotic Antagonists; D009270:Naloxone; D009020:Morphine; D019001:Nitric Oxide Synthase; D020104:Immunophilins; C004479:pimagedine; D019331:NG-Nitroarginine Methyl Ester; D016559:Tacrolimus